Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: The Patient Reported Outcomes Measurement Information System (PROMIS) initiative has developed and calibrated item banks for the assessment of physical function and other domains chronic diseases. Our objective was to assess the construct validity of PROMIS 20 items for physical function (PROMIS PF-20) in patients with early rheumatoid arthritis (RA).
Methods: RA patients who fulfilled the ACR/EULAR 2010 classification criteria, with <2 years from first patient reported swollen joint and who were DMARD naïve with indication for DMARD treatment were included in the tight control treat-to-target ARCTIC trial. The 230 patients were at baseline assessed with PROMIS PF-20 which had been translated to Norwegian according to recommended procedures. Other assessments were disease activity score based on 44 joints (DAS), patient global assessment of disease activity, investigator global assessment, pain and fatigue on 100 mm visual analogue scales, and health related quality of life (SF-36) with physical (SF-36 PCS) and mental (SF-36 MCS) component summaries. Patients were grouped according to DAS as low (<2.4), moderate (>2.4 and <3.7), and high (>3.7) disease activity. Pearson’s correlation coefficient is used to assess correlations, and Analysis of Variance (ANOVA) to assess difference between DAS groups.
Results: The mean (SD) age for the 230 patients in ARCTIC was 51.4 (13.7) years, disease duration 7.1 (5.4) months, DAS 3.5 (2.0), 61.0% were females and 82.2% anti-CCP positive. Correlations between PROMIS PF-20 and many other outcomes were mainly moderate to high (patient global -0.68, pain -0.66, SF-physical functioning scale 0.83, and SF-36 PCS 0.82), but associations were lower for investigator global -0.44, fatigue -0.38, and SF-36 MCS 0.23 (all p<0.001). The table shows how higher DAS levels discriminate PROMIS PF-20 and other outcomes. Table: Scores according to disease activity groups (Means and SD)
|Low DAS N=43||Moderate DAS N=102||High DAS N=85||P-value (ANOVA)|
|PROMIS PF-20||46.0 (9.1)||40.4 (7.4)||34.0 (6.7)||<0.001|
|Patient global (VAS)||30.8 (21.1)||45.2 (21.2)||64.8 (20.4)||<0.001|
|Pain (VAS)||30.4 (21.9)||44.7 (21.2)||60.4 (21.6)||<0.001|
|Fatigue (VAS)||30.7 (28.1)||38.9 (26.4)||47.2 (30.2)||0.006|
|SF36 PCS (0-100)||43.5 (9.6)||37.7 (8.0)||31.0 (8.1)||<0.001|
|SF36 MCS (0-100)||49.7 (10.6)||49.9 (10.1)||47.9 (11.0)||0.39|
|Investigator global (VAS)||20.6 (11.7)||34.2 (14.2)||58.3 (16.5)||<0.001|
Conclusion: Evaluation of physical function applying the PROMIS PF-20 was feasible, and our results support construct validity of the instrument.
To cite this abstract in AMA style:Uhlig T, Olsen IC, Aga AB, Lillegraven S, Kvien TK, Haavardsholm EA. Performance of the Patient Reported Outcomes Measurement Information System (PROMIS) Measure for Physical Function in Early RA [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/performance-of-the-patient-reported-outcomes-measurement-information-system-promis-measure-for-physical-function-in-early-ra/. Accessed November 28, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-the-patient-reported-outcomes-measurement-information-system-promis-measure-for-physical-function-in-early-ra/